These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25515506)

  • 21. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
    Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
    Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gauging reactive metabolites in drug-induced toxicity.
    Eno MR; Cameron MD
    Curr Med Chem; 2015; 22(4):465-89. PubMed ID: 25174933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The generation, detection, and effects of reactive drug metabolites.
    Stachulski AV; Baillie TA; Park BK; Obach RS; Dalvie DK; Williams DP; Srivastava A; Regan SL; Antoine DJ; Goldring CE; Chia AJ; Kitteringham NR; Randle LE; Callan H; Castrejon JL; Farrell J; Naisbitt DJ; Lennard MS
    Med Res Rev; 2013 Sep; 33(5):985-1080. PubMed ID: 23090860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism and Bioactivation: It's Time to Expect the Unexpected.
    Driscoll JP; Sadlowski CM; Shah NR; Feula A
    J Med Chem; 2020 Jun; 63(12):6303-6314. PubMed ID: 32267691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass spectrometry imaging in drug development.
    Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
    Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
    [No Abstract]   [Full Text] [Related]  

  • 26. A "White Knight" role for DMPK researchers in pharmaceutical discovery: maximization of biomarker and translational M&S activities.
    Teramura T
    Drug Metab Pharmacokinet; 2012; 27(4):365-7. PubMed ID: 23268314
    [No Abstract]   [Full Text] [Related]  

  • 27. Editorial. Role of Drug Transport and Pharmacokinetics in Drug Efficacy and Safety Part 1.
    Liu C; He X
    Curr Drug Metab; 2015; 16(9):730-1. PubMed ID: 26630904
    [No Abstract]   [Full Text] [Related]  

  • 28. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
    Pessayre D; Benhamou JP
    C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatopathies and drugs].
    González Macias J; De Castro del Pozo S
    Rev Esp Enferm Apar Dig; 1974; 44(2):175-86. PubMed ID: 4418081
    [No Abstract]   [Full Text] [Related]  

  • 30. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug discovery projects. Preface.
    Lawton G; Witty DR
    Prog Med Chem; 2011; 50():v-vi. PubMed ID: 21476319
    [No Abstract]   [Full Text] [Related]  

  • 33. Drugs and the liver.
    Papich MG; Davis LE
    Vet Clin North Am Small Anim Pract; 1985 Jan; 15(1):77-95. PubMed ID: 3872507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles of drug therapy for the elderly patient.
    Bressler R; Bahl JJ
    Mayo Clin Proc; 2003 Dec; 78(12):1564-77. PubMed ID: 14661688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs and the liver: a review of metabolism and adverse reactions.
    Schaffner F; Raisfeld IH
    Adv Intern Med; 1969; 15():221-51. PubMed ID: 4908619
    [No Abstract]   [Full Text] [Related]  

  • 36. Uremia and the liver. II. Drugs and the liver in the uremic patient.
    Simon P; Meyrier A; Brissot P
    Nephron; 1981; 29(1-2):7-13. PubMed ID: 7035980
    [No Abstract]   [Full Text] [Related]  

  • 37. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
    Williams DP; Park BK
    Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of acid/base properties in drug discovery.
    Manallack DT; Prankerd RJ; Yuriev E; Oprea TI; Chalmers DK
    Chem Soc Rev; 2013 Jan; 42(2):485-96. PubMed ID: 23099561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric mice with humanized liver: Application in drug metabolism and pharmacokinetics studies for drug discovery.
    Naritomi Y; Sanoh S; Ohta S
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):31-39. PubMed ID: 29183653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.